Patent · US Active

Antibodies targeting ActRIIA and ActRIIB

US12304958B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Six Peaks Bio AG · CH

Inventors

Christian Carsten Silvester KUNZ · Munich, DE
Amélie WIEDERKEHR · Ranspach-le-Bas, FR
Lisa WELLINGER · Basel, CH
Anne Laure LAINÉ · Huningue, FR
Emily RADKE · Lebanon, US
Caitlin Stein · Clarkston, US
Arvind Sivasubramanian · Santa Clara, US

Key dates

Filing date	Nov 13, 2024
Grant date	May 20, 2025
Priority date	—
Expiry date	Nov 13, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure relates to antibodies and antibody fragments that are specific for ActRIIA and ActRIIB. The antibodies are improved versions of bimagrumab. Antibodies of the present invention have an improved affinity against ActRIIA, translating into improved in vitro potency and efficacy, an improved PK and PD profile and a higher stability making the antibodies suitable for s.c. administration. Optionally they carry Fc modifications making the antibodies safe for prolonged treatments.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.